Silvan Tuerkcan
Stock Analyst at JMP Securities
(1.46)
# 3,322
Out of 4,865 analysts
169
Total ratings
36.59%
Success rate
-10.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELEV Elevation Oncology | Reiterates: Market Perform | n/a | $0.38 | - | 8 | Jun 10, 2025 | |
| SLDB Solid Biosciences | Reiterates: Market Outperform | $15 | $4.60 | +226.44% | 3 | Jun 6, 2025 | |
| NUVB Nuvation Bio | Reiterates: Market Outperform | $6 | $1.71 | +250.88% | 2 | Jun 2, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Market Outperform | $5 → $6 | $2.56 | +134.83% | 13 | May 29, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $43.19 | +99.12% | 15 | May 21, 2025 | |
| PRME Prime Medicine | Maintains: Market Outperform | $10 → $6 | $1.62 | +271.52% | 3 | May 20, 2025 | |
| BNTC Benitec Biopharma | Reiterates: Market Outperform | $20 | $15.24 | +31.23% | 12 | May 15, 2025 | |
| FHTX Foghorn Therapeutics | Reiterates: Market Outperform | $9 | $4.80 | +87.50% | 3 | May 15, 2025 | |
| VOR Vor Biopharma | Downgrades: Market Perform | $6 | $0.21 | +2,809.80% | 12 | May 9, 2025 | |
| ENGN enGene Holdings | Reiterates: Market Outperform | $18 | $3.23 | +457.28% | 4 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $20 | $3.90 | +412.82% | 12 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $41 | $41.36 | -0.86% | 21 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $1.21 | +1,310.79% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $0.38 | - | 8 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $70 | $5.42 | +1,191.51% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $0.59 | +573.97% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $3.06 | +586.27% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.37 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $1.36 | +341.18% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $289.40 | -3.25% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $10.65 | +69.01% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $9.58 | - | 10 | Jan 19, 2023 |
Elevation Oncology
Jun 10, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.38
Upside: -
Solid Biosciences
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $4.60
Upside: +226.44%
Nuvation Bio
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $1.71
Upside: +250.88%
Taysha Gene Therapies
May 29, 2025
Maintains: Market Outperform
Price Target: $5 → $6
Current: $2.56
Upside: +134.83%
CRISPR Therapeutics AG
May 21, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $43.19
Upside: +99.12%
Prime Medicine
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $1.62
Upside: +271.52%
Benitec Biopharma
May 15, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $15.24
Upside: +31.23%
Foghorn Therapeutics
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $4.80
Upside: +87.50%
Vor Biopharma
May 9, 2025
Downgrades: Market Perform
Price Target: $6
Current: $0.21
Upside: +2,809.80%
enGene Holdings
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $3.23
Upside: +457.28%
Apr 21, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $3.90
Upside: +412.82%
Apr 17, 2025
Reiterates: Market Outperform
Price Target: $41
Current: $41.36
Upside: -0.86%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $1.21
Upside: +1,310.79%
Mar 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.38
Upside: -
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $70
Current: $5.42
Upside: +1,191.51%
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $0.59
Upside: +573.97%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $3.06
Upside: +586.27%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.37
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $1.36
Upside: +341.18%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $289.40
Upside: -3.25%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $10.65
Upside: +69.01%
Jan 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $9.58
Upside: -